These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
52 related articles for article (PubMed ID: 1301015)
21. Ciprofloxacin resistance among nosocomial Pseudomonas aeruginosa and Staphylococcus aureus in the United States. Blumberg HM; Rimland D Infect Control Hosp Epidemiol; 1995 Nov; 16(11):620-1. PubMed ID: 8601677 [No Abstract] [Full Text] [Related]
22. Late quinolone resistance in Pseudomonas aeruginosa. Smith JM; Hashmi ZS J Antimicrob Chemother; 1991 Apr; 27(4):555-6. PubMed ID: 1906859 [No Abstract] [Full Text] [Related]
23. Drug resistance of Pseudomonas aeruginosa with special reference to new quinolones. Iyobe S; Hirai K; Hashimoto H Antibiot Chemother (1971); 1991; 44():209-14. PubMed ID: 1801639 [No Abstract] [Full Text] [Related]
24. [Study on new quinolone-resistant strains isolated from urine--annual changes of its frequency and the relation to drug volume]. Chujoh T; Hirose T; Kumamoto Y; Tsukamoto T; Uehara N; Maruta H; Koroku M; Matsuda K Kansenshogaku Zasshi; 1990 Nov; 64(11):1416-24. PubMed ID: 2126798 [TBL] [Abstract][Full Text] [Related]
25. Mode of action and development of resistance to quinolones. Cullmann W Antibiot Chemother (1971); 1989; 42():287-300. PubMed ID: 2512843 [No Abstract] [Full Text] [Related]
26. Minimizing quinolone resistance: are the new agents more or less likely to cause resistance? Thomson KS J Antimicrob Chemother; 2000 Jun; 45(6):719-23. PubMed ID: 10837422 [No Abstract] [Full Text] [Related]
27. Quinolones for the treatment of infections due to Salmonella. Cherubin CE; Eng RH Rev Infect Dis; 1991; 13(2):343-4. PubMed ID: 2041971 [No Abstract] [Full Text] [Related]
28. [Reconsiderations on chemotherapy]. Mikata K Nihon Ishikai Zasshi; 1965 Dec; 54(11):1239-43. PubMed ID: 5895209 [No Abstract] [Full Text] [Related]
29. Risk/benefit analysis of quinolone use in children: the effect on diarthrodial joints. Maggiolo F; Caprioli S; Suter F J Antimicrob Chemother; 1990 Oct; 26(4):469-71. PubMed ID: 2254219 [No Abstract] [Full Text] [Related]
30. Quantifying the impact of resistance for prescribers and drug developers-a function of natural resolution rates. Turnidge JD J Antimicrob Chemother; 2000 Jun; 45(6):925-6. PubMed ID: 10837456 [No Abstract] [Full Text] [Related]
31. The future of antibacterial chemotherapy. Slocombe B Zentralbl Bakteriol; 1994 Oct; 281(3):346-52. PubMed ID: 7696756 [No Abstract] [Full Text] [Related]
32. Bacterial resistance to the quinolone antimicrobial agents. Hooper DC; Wolfson JS Am J Med; 1989 Dec; 87(6C):17S-23S. PubMed ID: 2690616 [TBL] [Abstract][Full Text] [Related]
33. Quinolone resistance: an alternative perspective. Fish DN; Piscitelli SC; Danziger LH Arch Intern Med; 1992 Jun; 152(6):1329-30. PubMed ID: 1301015 [No Abstract] [Full Text] [Related]